Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $3.34 million versus the consensus estimate of $2.38 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• CVG to join Russell 2000 and Russell 3000 indexes June 26